New Listings
New listings during S2 2013 on Euronext
Date |
Company |
Activity sector |
Operation |
Amount raised |
Capitalisation* |
4.07 |
Norbert Dentressangle |
Transportation |
Dual listing |
0 |
€605 M |
5.07 |
Orège |
Waste services |
Global offering |
€20.1 M |
€57.7 M |
5.07 |
Cardio3 BioSciences |
Biotechnology |
Global offering |
€23 M |
€101.9 M |
10.10 |
BTG Pactual |
Banking |
Transfer from Alternext |
0 |
- |
30.10 |
Blue Solutions |
Energy storage |
Global offering |
€41.8 M |
€418 |
8.11 |
Numéricable |
Broadband services |
Global offering |
€750 M |
€3 530 M |
22.11 |
Tarkett |
Floor solutions |
Global offering |
€461 M |
€1 800 M |
25.11 |
Implanet |
Medical techology |
Global offering |
€14.1 M |
€39 M |
25.11 |
Viohalco |
Metal industry |
Merger transaction |
0 |
€920 M |
29.11 |
Medtech |
Medical technology |
Global offering |
€20 M |
€64.5 M |
12.12 |
SnowWorld |
Leisure industry |
Reverse takeover |
0 |
€5.1 M |
17.12 |
Montepio |
Banking |
Participation units |
€200 M |
€196 M |
The CEOs comment their operations:
Hervé Montjotin CEO of Norbert Dentressangle: “We believe our listing on Euronext London will raise the profile of Norbert Dentressangle amongst the UK investment community who have a wealth of experience in the transport, logistics and supply chain sector.”
Pascal Gendrot, Co-founder and CEO of Orège: “Listing represents a major step ahead in our company's business development, and is clearly a springboard for structuring new strategic partnerships.”
Christian Homsy, CEO of Cardio3 BioSciences: “It is with great pride that we announce our listing in Brussels and in Paris. We are the first biotechnology company to list on both exchanges and welcome our new investors both institutional and private individuals.”
João Dantas, Executive Officer and Investor Relations Officer of BTG Pactual: “This transfer is a testimony to our continued cooperation with Euronext in Europe.”
Vincent Bolloré, Chairman of Blue Solutions: “After twenty years of hard work and R&D, our teams at Blue Solutions, with their unique expertise and know-how, are immensely proud to see their work listed on Euronext in Paris.”
Eric Denoyer, Chairman and CEO of Numericable Group: “Thanks to listing on Euronext and this capital increase we will be accelerating our investments over the next three years to strengthen our existing lead.”
Michel Giannuzzi, Head of Tarkett’s Management Board: “Today, Tarkett benefits from all of the strengths necessary to pursue its profitable, sustainable growth dynamic: a healthy, solid financial structure, a balanced geographical presence and a broad portfolio of solutions in the flooring and sports surface markets.”
Ludovic Lastennet, CEO of Implanet: “I am very happy with Implanet’s successful listing on Euronext where the number of health stocks has grown steadily and expanded its reach with international investors.”
Jacques Moulaert, Vice-president and Executive Director of Viohalco: “We strongly believe that Viohalco’s listing in Brussels today will boost its visibility and enhance its access to international capital markets.”
Bertin Nahum, Chairman & CEO and founder of Medtech: “I would like to thank all of the institutional and individual shareholders that have joined us, as well as all of our staff and partners, for their contributions to the success of our IPO.”
Koos Hendriks, CEO of SnowWorld: “The listing on Euronext Amsterdam is the basis of our ambition to realize the roll out of the SnowWorld concept in Europe.”
António Tomás Correia, Chairman of Montepio: “It is the first time that Montepio has equity capital listed on a stock exchange. It is a matter of great satisfaction for us and it establishes and strengthens our confidence in the future, taking into account the high number of subscribers - more than 25,000 - which shows the power of the brand”.
New listings during S2 2013 on Alternext
Date |
Company |
Activity Sector |
Operation |
Amount raised |
Capitalisation* |
2.09 |
Medical Device Works |
Medical equipment |
Private placement |
€2.5 M |
€11.5 M |
13.11 |
RocTool |
Industrial machinery |
Transfer from the Free Market |
€3.6 M |
€24.7 M |
9.12 |
Entreprendre Lafont Presse |
Publishing |
Transfer from the Free Market |
0 |
€25.4 M |
17.12 |
Carbios |
Green chemistry |
Global Offering |
€13.1 M |
€52.4 M |
23.12 |
Figeac Aéro |
Aerospace |
Private placement |
€17.6 M |
€244.5 M |
The CEOs comment their operation:
Hervé de Kergrohen, CEO of Medical Device Works: “Our technology - a unique approach designed to treat liver cancer more effectively by repeated isolation of the organ - has been developed with the support of our traditional shareholders and clinical partners. It will now benefit from the visibility offered by stock-exchange listing."
Alexandre Guichard, Chairman of RocTool: “Our transfer to Alternext and related capital increase have boosted RocTool’s credibility and will enable us to pursue a growth strategy focusing on international markets.”
Robert Lafont, Chairman and CEO of Entreprendre-Lafont Presse: “Our transfer to Alternext opens a new stage in our experience on the stock market. In today’s economy, it not only boosts our credibility, it also gives us the clout and support we need to face the new challenges in our sector.”
Jean-Claude Lumaret, Carbios CEO and founder: “Our successful listing gives us the resources we need to become a leading player in the world’s plastics and recycling markets.”
Jean-Claude Maillard, Chairman and CEO of Figeac Aéro: “The increased financial resources that result from this listing will allow us to step up the pace of growth and above all to deploy our strategy aimed at becoming a world leader in subcontracted services to the aerospace industry.”